Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients

Figure 2 Retrospective study on the probability of cardiovascular thrombotic event-free survival (days up to 3600 d = 10 years) according to the JAK2^V617F mutational state in 323 polycythemia vera and 639 essential thrombocythemia patients (Vannucchi et al[20]). Only major thrombotic events were retrospectively recorded and the erythromelalgic peripheral, ocular and cerebral ischemic events were excluded from evaluation. The overall incidence of major thrombotic events in JAK2^V617F mutated PV patients during 10 years follow-up is about 25% in the Italian study[20]. A similar incidence of thrombotic events was found in our literature analysis of 1241 ET patients not on aspirin from 14 retrospective studies[22]. Source Vannucchi et al[20] Blood 2007. ET: Essential thrombocythemia; PV: Polycythemia vera.